Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC + JS001 in perioperative muscle-invasive bladder cancer
NCT05297552Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in muscle-invasive bladder cancer (MIBC), sponsored by RemeGen. Primary endpoint: Pathologic Complete Response (pCR) Rate at 16 weeks. Started May 2022; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05297552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297552.